Duodenal Patents (Class 514/926)
  • Patent number: 8648080
    Abstract: The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention relates to the method of prevention or treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agent. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof for the prevention or treatment of said diseases.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: February 11, 2014
    Assignee: RaQualia Pharma Inc.
    Inventors: Nobuyuki Takahashi, Shinichi Koizumi
  • Patent number: 8372429
    Abstract: An agent for treating ulcer containing, as an effective component, a particulate composite hydrotalcite obtained by solidly dissolving a small amount of zinc in the particulate hydrotalcite, exhibiting excellent effect for treating the peptic ulcer and, further, working as a Zn-supplying agent. The agent for treating the ulcer is represented by the following formula (1), (MgaZnb)1-xAlx(OH)2(An?)x/n.mH2O??(1) wherein An? is CO32?, SO42? or Cl?, n is 1 or 2, and x, a, b and m are values that satisfy the following conditions, 0.18?x?0.4, 0.1?a<1, 0<b?0.5, 0?m<1.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: February 12, 2013
    Assignee: Kyowa Chemical Industry Co., Ltd.
    Inventors: Keiko Katsuki, Akira Okada
  • Patent number: 8216608
    Abstract: A novel particulate composite hydrotalcite which offers antacidic effect comparable to that of a particulate hydrotalcite so far used as a gastric antacid and, further, offers excellent stomach inner wall protection effect. A particulate composite hydrotalcite represented by the following formula (1), (MgaZnb)1-xAlx(OH)2(An?)x/n.mH2O??(1) wherein An? is CO32?, SO42? or Cl?, n is 1 or 2, and x, a, b and m are values that satisfy the following conditions, 0.18?x?0.4, 0.5?a<1, 0<b?0.5, 0?m<1, and a gastric antacid using the particulate composite hydrotalcite as an effective component. When used as a gastric antacid, the particulate composite hydrotalcite suppresses the occurrence of damage in the mucous membranes of stomach and intestines.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: July 10, 2012
    Assignee: Kyowa Chemical Industry Co., Ltd.
    Inventors: Akira Okada, Keiko Katsuki
  • Patent number: 8187614
    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 29, 2012
    Assignee: Legere Pharmaceuticals, Ltd.
    Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
  • Patent number: 7803574
    Abstract: This invention provides novel nanofiber enhanced surface area substrates and structures comprising such substrates for use in various medical devices, as well as methods and uses for such substrates and medical devices. In one particular embodiment, a method of administering a composition to a patient is disclosed which comprises providing a composition-eluting device, said composition-eluting device comprising at least a first surface and a plurality of nanostructures attached to the first surface, and introducing the composition-eluting device into the body of the patient.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: September 28, 2010
    Assignee: Nanosys, Inc.
    Inventors: Tejal Desai, R. Hugh Daniels, Vijendra Sahi
  • Patent number: 7790672
    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: September 7, 2010
    Assignee: Legere Pharmaceuticals, Inc.
    Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
  • Patent number: 7544710
    Abstract: The present invention relates to the use of the distrontium salt of 2-[N,N-di(carboxymethyl)amino]-3-cyano-4-carboxymethyl-thiophene-5-carboxylic acid in obtaining medicaments intended for the treatment of gastro-duodenal pain.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: June 9, 2009
    Assignee: Les Laboratoires Servier
    Inventor: Yannis Tsouderos
  • Patent number: 7351723
    Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: April 1, 2008
    Assignee: Nycomed GmbH
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 6855347
    Abstract: The present invention relates to a novel synergistic herbal composition for the treatment of gastric ulcer, a method for preparing said synergistic herbal composition and a process for the treatment of gastric ulcer using said composition and more particularly, the present invention relates to a novel synergistic herbal composition which is effective against pyloric ligation induced ulcer model and histamine induced ulcer model.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: February 15, 2005
    Assignee: Council of Scientific and Industrial Research
    Inventors: Janaswamy Madhusudana Rao, Upparapalli Sampathkumar, Boggavarapu Subrahmanya Sastry, Jhillu Singh Yadav, Kondapuram Vijaya Raghavan, Gautam Palit, Deepak Rai, Panniyampally Madhavankutty Varier, Trikovil Sankaran Muraleedharan, Kollath Muraleedharan
  • Patent number: 6780881
    Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: August 24, 2004
    Assignee: Altana Pharma AG
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 6767559
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: July 27, 2004
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6696486
    Abstract: The present invention relates to the use of compounds which act as agonists at atypical beta-adrenoceptors, for the treatment of gastrointestinal disorders, especially peptic ulceration, oesophagitis, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and gastrointestinal ulcerations, especially when induced by non-steroidal anti-inflammatory drugs or corticosteroids.
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: February 24, 2004
    Assignee: Glaxo Group Limited
    Inventor: Ashwani Kumar Bahl
  • Patent number: 6593339
    Abstract: The present invention discloses a new use of NO-releasing NSAIDs, especially NO-releasing NSAIDs of the formula I, or a pharmaceutically acceptable salt or enantiomer thereof, for the manufacture of a medicament for the treatment of bacterial infections, especially caused or mediated by Helicobacter pylon. Disclosed is also the new use of a NO-releasing NSAID in combination with an acid susceptible proton pump inhibitor for the treatment of bacterial infections.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: July 15, 2003
    Assignee: AstraZeneca AB
    Inventors: Arne Eek, Johan Raud
  • Patent number: 6555534
    Abstract: The use of 4,4-methylenebis (tetrahydro-1,2-4-thiadiazine-1,1 -dioxide) in the eradication and control of the microorganism Helicobacter pylori in humans is disclosed.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: April 29, 2003
    Assignee: Medpointe Healthcare Inc.
    Inventor: James C. Costin
  • Patent number: 6518250
    Abstract: An agent for preventing and curing the hindrance of ischemic reperfusiton is disclosed which has as an active component thereof a chromanol glycoside represented by the following general formula: [wherein R1, R2, R3, and R4 independently denote a hydrogen atom or a lower alkyl group, R5 denotes a hydrogen atom, a lower alkyl group, or a lower acyl group, X denotes a monosaccharide residue or an oligosaccharide residue which may have a lower alkyl group or a lower acyl group substituted for the hydrogen atom of the hydroxyl group of the saccharide residue, n denotes an integer of 0-6, and m denotes an integer of 1-6]. The agent, even in a small dosage, acts safely and effectively on the affected part and allows the hindrances of ischemic reperfusion induced in heart, stomach, small intestine, liver, spleen, kidney, brain, and skin, and the hindrance induced during the transplantation of an internal organ to be prevented and cured.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: February 11, 2003
    Assignee: CCI Corporation
    Inventors: Toshikazu Yoshikawa, Hironobu Murase, Norimasa Yoshida
  • Patent number: 6515008
    Abstract: The present invention is directed to a novel pharmaceutical composition of polymorph B which has been found to be stable and palatable for long term commercial usage.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: February 4, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Antonio S. Tiongson, Chungbin Kim
  • Patent number: 6498171
    Abstract: Methods and compositions are disclosed utilizing hydroxyomeprazole for the treatment of ulcers in humans. Hydroxyomeprazole exhibits a lessened liability toward drug-drug interactions than omeprazole and a more predictable dosing regimen than omeprazole. Hydroxyomeprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: December 24, 2002
    Assignee: Sepracor Inc.
    Inventors: William E. Yelle, Dean A. Handley
  • Patent number: 6489317
    Abstract: The invention provides methods for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with Helicobacter pylori in a patient requiring said treatment and/or prevention, which comprise administering to the patient a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent. The invention also provides pharmaceutical compositions for use in the methods of the invention.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: December 3, 2002
    Inventor: Thomas Julius Borody
  • Patent number: 6471955
    Abstract: This invention provides a method of preparing a polymeric delivery system for active ingredients having enhanced site specific release performance characteristics. The delivery system is formed either by attaching the active ingredient to a linker through an acid-sensitive covalent bond, then forming a covalent bond between the linker and a portion of the subunits of a crosslinked polystyrene polymer, or by attaching a linker to a portion of the subunits of a crosslinked polystyrene polymer, then attaching the active ingredient to the polymer-linker combination through an acid-sensitive covalent bond. The invention also provides a delivery system comprising an active ingredient covalently bonded through an acid-sensitive covalent bond to a linker, which is in turn covalently bonded to a portion of subunits of a crosslinked polystyrene polymer.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: October 29, 2002
    Assignee: Pharmacia Corporation
    Inventors: Samuel J. Tremont, Denis Forster, Ricky L. Fenton, Yinong Ma
  • Patent number: 6468964
    Abstract: According to the present invention there is provided a method for the treatment or prophylaxis of acidic gut syndrome resulting from the accumulation of acid and production of endotoxin in the gastrointestinal tract of a human or an animal, said accumulation resulting from the fermentation of carbohydrate in the gastrointestinal tract of said human or animal, wherein said method comprises administering to said human or animal an effective amount of an active agent capable of preventing or controlling acid and endotoxin accumulation in the gastrointestinal tract.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: October 22, 2002
    Assignee: University of New England, of Armidale
    Inventor: James Baber Rowe
  • Patent number: 6444232
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: September 3, 2002
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6420435
    Abstract: Methods of treating gastrointestinal disorders (e.g. heart bum, GERD, and gastric indigestion) comprising orally administering therapeutically effective amounts of limonene are described herein.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: July 16, 2002
    Inventor: Joe S. Wilkins, Jr.
  • Patent number: 6379651
    Abstract: The invention relates to concomitant treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics in oral-topical and peroral dosage forms to eradicate H. pylori from its niches both in the dental plaque and in the gastric mucosa in order to improve the ulcer cure rate and prevent ulcer relapse. The invention also provides oral topical dosage forms with pharmaceutically usable bismuth compounds, other antibacterial compounds, and/or antibiotics that eradicate or reduce H. pylori in dental plaque. The invention further provides for treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics which are effective against Campylobacter rectus and Treponema denticola which are responsible for causing halitosis. The invention also provides bismuth compounds which have applications in wound healing, particularly in ocular and dermal wound healing.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: April 30, 2002
    Assignee: Josman Laboratories
    Inventor: Narayan Athanikar
  • Patent number: 6365201
    Abstract: A phytochemical composition for management of peptic ulcer conditions in humans is provided. The composition is a hot water extract of powdered Indigofera arrecta plant leaves. The extract may be prepared by contacting the powdered leaves with hot water for a period of time, filtering the extraction mixture, concentrating the filtrate in vacuo and freeze drying the concentrated filtrate. The extract is admixed with magnesium carbonate, dried maize starch, talc and magnesium stearate to form a homogenous mass which is filled into capsules. The capsules are ingested orally to provide an analgesic effect. Also described are methods for making the extract and the methodology for using the extract.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: April 2, 2002
    Assignee: National Institute for Pharmaceutical Research and Development
    Inventors: Charles O. N. Wambebe, Shingu K. Gamaniel, Peter Akah, Dogara S. Fumen, Hafsatu Shittu
  • Patent number: 6291517
    Abstract: A method is disclosed for preventing and/or reducing stress-induced gastric injury by administering an amount of grape seed proanthocyanidin extract effective to inhibit injury is administered to persons identified as among those with or at risk for such injury.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: September 18, 2001
    Assignee: Dry Creek Nutrition, Inc
    Inventors: Debasis Bagchi, Manashi Bagchi, Sidney J. Stohs
  • Patent number: 6160017
    Abstract: The invention relates to an agent for preventing and treating ulcerous colitis and/or Crohn's disease, comprising conagenin or a pharmaceutically acceptable salt thereof as an active ingredient. According to the present invention, there is provided an agent for preventing and treating ulcerous colitis and/or Crohn's disease, which has high therapeutic effect and safety.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: December 12, 2000
    Assignees: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Taiho Pharmaceutical Co., Ltd.
    Inventors: Masaaki Ishizuka, Kenji Maeda, Tomio Takeuchi, Tadayoshi Shiraishi, Masakazu Fukushima
  • Patent number: 6147053
    Abstract: The invention relates to active substance combinations which consist of at least one polypeptide with the biological action of fibroblast growth factors and of at least one cationic polyelectrolyte. These combinations permit improved dosage of the FGF activity.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: November 14, 2000
    Assignee: Merck Patent Gesellschaft MIT
    Inventor: Berthold Nies
  • Patent number: 6117868
    Abstract: A method and composition for the treatment of infectious gastrointestinal ulcer disease or infectious gastritis disease of microbially infected gastrointestinal tissue in a mammal involves administration of an antimicrobial amount of an antimicrobial medicament which is cell wall constituent-inactivating by chemical reaction with cell wall constituents, endotoxin non-releasing, exotoxin-inactivating or a combination thereof.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: September 12, 2000
    Assignee: Ed. Geistlich Sohne AG fur chemische Industrie
    Inventor: Rolf W. Pfirrmann
  • Patent number: 6110891
    Abstract: This invention provides methods for: the control of mucosal cell proliferation; the reduction and/or treatment of damage caused by a cell-damaging agent; and for the reduction and/or treatment of a metabolic disorder.The methods comprise administering to an individual in need of control or reduction and/or treatment on effective amount of a lectin.The invention takes advantageous of the protective and repair capabilities of lectins. It is particularly useful in the prevention and treatment of animals undergoing radiotherapy and/or chemotherapy for cancer.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: August 29, 2000
    Assignee: Alizyme Therapeutics Ltd.
    Inventors: Arpad Janos Pusztai, Zsuzsanna Magdolna Bardocz, Richard Michael John Palmer, Neil William Fish, Gyorgy J. Koteles
  • Patent number: 6110506
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: August 29, 2000
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6086882
    Abstract: A phytochemical composition for management of peptic ulcer conditions in humans is provided. The composition is a hot water extract of powdered Indigofera arrecta plant leaves. The extract may be prepared by contacting the powdered leaves with hot water for a period of time, filtering the extraction mixture, concentrating the filtrate in vacuo and freeze drying the concentrated filtrate. The extract is admixed with magnesium carbonate, dried maize starch, talc and magnesium stearate to form a homogenous mass which is filled into capsules. The capsules are ingested orally to provide an analgesic effect. Also described are methods for making the extract and the methodology for using the extract.
    Type: Grant
    Filed: August 6, 1997
    Date of Patent: July 11, 2000
    Assignee: National Institute for Pharmaceutical Research
    Inventors: Charles O. N. Wambebe, Shingu K. Gamaniel, Peter Akah, Dogara S. Fumen, Hafsatu Shittu
  • Patent number: 6083509
    Abstract: A phytochemical composition for management of peptic ulcer conditions in humans is provided. The composition is a hot water extract of powdered Indigofera arrecta plant leaves. The extract may be prepared by contacting the powdered leaves with hot water for a period of time, filtering the extraction mixture, concentrating the filtrate in vacuo and freeze drying the concentrated filtrate. The extract is admixed with magnesium carbonate, dried maize starch, talc and magnesium stearate to form a homogenous mass which is filled into capsules. The capsules are ingested orally to provide an analgesic effect. Also described are methods for making the extract and the methodology for using the extract.
    Type: Grant
    Filed: January 11, 1999
    Date of Patent: July 4, 2000
    Assignee: National Institute for Pharmaceutical Research and Development
    Inventors: Charles O. N. Wambebe, Shingu K. Gamaniel, Peter Akah, Dogara S. Fumen, Hafsatu Shittu
  • Patent number: 6071953
    Abstract: Chromans of formula I ##STR1## with the meanings of R(A), R(B) and R(1) to R(8) stated in the specification are suitable for producing a medicament for blocking the K.sup.+ channel that is opened by cyclic adenosine monophosphate (cAMP); also for producing medicaments for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and the intestinal region, in particular the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal disorders, for the treatment and prevention of all types of arrhythmias, including atrial, ventricular and supraventricular arrhythmias, for controlling reentry arrhythmias and for preventing sudden heart death as a result of ventricular fibrillation.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: June 6, 2000
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Hans Jochen Lang, Joachim Brendel, Uwe Gerlach, Klaus Weidmann
  • Patent number: 6048552
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: April 11, 2000
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6043243
    Abstract: A pyrrolidine derivative or a salt thereof expressed by the following formula 1: ##STR1## wherein R.sub.1 is an alkenyl group; R.sub.2 is a lower alkoxy group or a halogen atom;R.sub.3 is a lower alkyl group;X is a group expressed by --O-- or --S--;Y is carbon or nitrogen atom;m is an integer of 1 to 3; andn is an integer of 0 to 2.The pyrrolidine derivative has an anti-ulcer effect or an antibacterial activity against Helicobacter pyroli, and has also high safety to be available for prevention or cure of ulcers.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: March 28, 2000
    Assignee: Shiseido Co., Ltd.
    Inventors: Chikao Nishino, Tomohiro Uetake
  • Patent number: 6013680
    Abstract: To provide a medicament that can be used as a drug for the effective treatment of gastric ulcers, duodenal ulcers and like diseases of the digestive tract. The medicament comprises a combination of at least one agent selected from the group consisting of histamine H.sub.2 receptor antagonists and proton pump inhibitors, and a digestive enzyme.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: January 11, 2000
    Assignee: Amano Pharmaceutical Co., Ltd.
    Inventors: Tomonari Ogawa, Kinya Kariya, Susumu Okabe
  • Patent number: 5968906
    Abstract: Sucralfate containing preparations which contain both an organic acid having at least two carboxyl groups or at least one carboxyl group in the molecule and sucralfate are described. The sucralfate containing preparations have enhanced sucralfate adhesion to the mucosal ulcer site even under a nonacidic condition and can be extensively applied not only to ulcers in the upper digestive tract such as esophagitis and duodenal ulcer but also to ulcers in the lower digestive tract such as proctitis and ulcerative colitis, as well as to dermal ulcers such as bedsores, stomatitis and the like.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: October 19, 1999
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Koji Kashimura, Koichi Ozawa
  • Patent number: 5935998
    Abstract: Use of compounds of formula (I), wherein R has various significances, in free base form or in pharmaceutically acceptable salt form, as agents against H. pylori infection and associated diseases.
    Type: Grant
    Filed: January 6, 1998
    Date of Patent: August 10, 1999
    Assignee: Novartis AG
    Inventors: Ivan James Dalton Lindley, Neil Stewart Ryder
  • Patent number: 5914135
    Abstract: Calcium carbonate liquid antacid compositions containing one or more pH adjusting agents to maintain the pH above 9.0, preferably above 9.5. The resultant antacid liquid possesses superior resistance to microbial attack and enhanced taste properties.
    Type: Grant
    Filed: April 16, 1997
    Date of Patent: June 22, 1999
    Assignee: McNeil-PPC, Inc.
    Inventors: John J. Dubek, Gerard P. McNally, Bruce P. Smith
  • Patent number: 5900413
    Abstract: An infection with Helicobacter may successfully be treated with a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or methyl and R.sub.2 is hydrogen or L-alanine-L-alanyl, and the pharmaceutically acceptable acid additive salts thereof. These compounds are useful in the treatment of gastric and duodenal ulcers.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: May 4, 1999
    Assignee: Pfizer Inc.
    Inventors: Arthur E. Girard, Thomas D. Gootz
  • Patent number: 5885960
    Abstract: The invention relates to active substance combinations which consist of at least one polypeptide with the biological action of fibroblast growth factors and of at least one cationic polyelectrolyte. These combinations permit improved dosage of the FGF activity. The invention also relates to a method of treating wounds, burns, skin ulcers, diabetic gangrene, mucosal ulcers and lesions, skin donation and transplantation sites, or surgical wounds by administering a peptide having FGF activity with an amount of cationic polyelectrolyte which is effective to decrease non-specific binding of the peptide having FGF activity.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: March 23, 1999
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventor: Berthold Nies
  • Patent number: 5871774
    Abstract: Medical materials for use in treating maladies in living beings, such as ulcers and other conditions of the digestive tract. In one form, a container is provided for a medication which container also contains an adhesive material which is operatively released from the container or exposed at the surface thereof upon biodegradation or dissolution of a protective coating or wall portion of the container under the effects of fluid in the digestive tract in which the container is exposed, such as by swallowing, to permit such adhesive to temporarily bond and retain the container at a select location in the digestive tract so that it may slowly release its contents thereafter to a select portion of the digestive tract. In another form, a multitude of microcapsules, each containing a small quantity of medication, is mixed with an adhesive material, such as a sulcralfate other material which may be swallowed as a tablet or dissolved in a liquid such as water.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: February 16, 1999
    Inventor: Jerome H. Lemelson
  • Patent number: 5858365
    Abstract: This invention is directed to methods of administering physiologically stable and safe compositions of butyric acid salts and derivatives to a patient for the purpose of wound healing.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 12, 1999
    Assignee: Trustees of Boston University
    Inventor: Douglas V Faller
  • Patent number: 5852004
    Abstract: Use of at least one polymer or one biopolymer, called HBGFPPs, specifically protecting the growth factors of families of FGFs and beta TGFs from tryptic degradation and not significantly inhibiting coagulation, in the manufacture of a drug for the treatment of lesions of the digestive tract and of primary or secondary derived tissues of the endoderm and the mesoderm.
    Type: Grant
    Filed: December 30, 1996
    Date of Patent: December 22, 1998
    Assignee: Societe Valbiofrance
    Inventors: Denis Barritault, Jean-Pierre Caruelle, Anne Meddahi
  • Patent number: 5843482
    Abstract: Complexes of bismuth, e.g. bismuth salts, and polyacrylate, e.g. carbomer, are discloses which may be incorporated into pharmaceutical compositions for oral, oral delayed-release, and rectal administration. The complexes may be combined with an antibiotic, such as tetracycline, and an antiprotozoal agent, e.g. Metronidazole, for use in the treatment of Helicobacter pylori infection. The treatment of inflammatory bowel disease using bismuth/polyacrylate complexes, or other bismuth preparations, is also described.
    Type: Grant
    Filed: January 21, 1993
    Date of Patent: December 1, 1998
    Assignee: Tillotts Pharma AG
    Inventors: John Rhodes, Brian Kenneth Evans
  • Patent number: 5837240
    Abstract: Methods and compositions are provided for prophylactic and antibacterial therapy for Helicobacter, particularly for Helicobacter pylori, infection of humans. The immunogenic composition of the invention is composed of a plurality of multimeric complexes, each complex being composed of recombinant, enzymatically inactive Helicobacter pylori urease. Each multimeric complex is composed of six Urease A subunits and six Urease B subunits. Alternatively, the composition is composed of a mixture of multimeric complexes, wherein each multimeric complex in the mixture is composed of six Urease A subunits and six Urease B subunits or four Urease A subunits and four Urease B subunits.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: November 17, 1998
    Assignee: OraVax-Merieux Co.
    Inventors: Cynthia K. Lee, Thomas P. Monath, Samuel K. Ackerman, William D. Thomas, Gopalan Soman, Harold Kleanthous, Richard A. Weltzin, Jacques Pappo, Thomas Ermak, Farshad Guirakhoo, Hitesh Bhagat, Ilene Sussman
  • Patent number: 5750535
    Abstract: The present invention relates to a method treating or preventing disorders caused by a spiral urease-positive gram-negative bacterium such as Helicobacter pylori in mammals, including humans, using compounds that are substance P receptor antagonists and, specifically, using certain quinuclidine derivatives, piperidine derivatives, pyrrolidine derivatives, azanorbornane derivatives, ethylene diamine derivatives and related compounds.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: May 12, 1998
    Assignee: Pfizer Inc.
    Inventor: Joanna Clancy
  • Patent number: 5728384
    Abstract: Ground germinated rice or an extract of polished rice or germinated rice are effective in preventing or treating ulcers.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: March 17, 1998
    Assignee: Soken Co., Ltd.
    Inventor: Takashi Tokuyama
  • Patent number: 5728711
    Abstract: An infection with Helicobacter may successfully be treated with a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or methyl and R.sub.2 is hydrogen or L-alanine-L-alanyl, and the pharmaceutically acceptable acid additive salts thereof. These compounds are useful in the treatment of gastric and duodenal ulcers.
    Type: Grant
    Filed: December 2, 1996
    Date of Patent: March 17, 1998
    Assignee: Pfizer Inc.
    Inventors: Arthur E. Girard, Thomas D. Gootz
  • Patent number: 5702911
    Abstract: The present invention relates to an improved test composition for the diagnosis of gastric ulcers, duodenal ulcers, gastritis, gastric lymphoma and gastric carcinoma by the detection of the bacteria Helicobacter pylori and the enzyme catalase associated with such conditions. The new test composition differs from the prior art agar compositions in being an aqueous solution containing hydrogen peroxide, urea, monobasic sodium phosphate and bromthymol blue as an indicator, and in being far more rapid than the prior art test compositions.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: December 30, 1997
    Assignee: Chek-Med Systems, Inc.
    Inventor: Robert G. Whalen